Gorham disease, also known as massive osteolysis, is characterized by unregulated proliferation of lymphatic or vascular capillaries within bone, resulting in destruction and replacement with angiomatous tissue. This disease can lead to chylothorax that can be lethal. Viscum album extract from European mistletoe is a complementary anti-cancer drug which is commonly prescribed in many European countries and is considered as a new generation of chemical agent for pleurodesis. A 14-year-old girl presented with dyspnea and chest pain. She was diagnosed as Gorham disease who was definitively treated with V. album extract for chylothorax that was refractory to standard conservative management.
lymphocytes.
The patient had been diagnosed as having Gorham disease when she was 5 years old. At that time, she had been suffering from high fever and dyspnea and had been diagnosed with left-side empyema. She had undergone decortication through a thoracotomy instead of videoassisted thoracoscopic surgery because of her severe pleural adhesions. After the operation, laboratory tests revealed a chylothorax in the left pleural space. She could be discharged four months after the operation because of long-term total parenteral nutrition for prolonged drainage of chyle. A computed tomography and bone scan demonstrated multifocal osteolytic lesions and fractures in the clavicle, scapula, humerus, ankle, hip, and sternum ( Figure 1B and C) . Furthermore, the left thoracic cage had a deformity caused by a previous thoracic surgery. Five months prior, the patient had been admitted to our pediatric department because of chylothorax in the right pleural cavity and managed with repeated pleural tapping and supportive care including total parenteral nutrition and interferon therapy. Interferon alpha-2b 250 million IU was injected through subcutaneous tissue six times over 14 days and 500 million IU three times over 7 days.
However, the pleural drainage persisted, and the patient suffered from fever, chills, and nausea. Two months after admission, the amount of pleural effusion was acceptably decreased on chest X-ray, but she could not tolerate the supportive care. The patient and her parents strongly wanted a discharge, and the patient was followed up regularly in the outpatient department.
In this time, we decided to perform a chemical pleurodesis using an extract of V. album (European mistletoe) (ABNOBA viscum F; ABNOBA Heilmittel Pforzheim, Germany) four days after the admission. Two ampoules of ABNOBA viscum F (100 mg) mixed with 200 ml normal saline were infused into the thoracic tube after the right lung was fully re-expanded. The repeated pleurodeses were performed at 3 and 8 days after the first pleurodesis through the similar manner. The amount of pleural drainage decreased constantly from over 1,000 ml per day to 40 ml per day. Five days after the last pleurodesis, we removed a chest tube because of the decreasing amount of pleural drainage despite the oral intake for 3 days. The patient was discharged 3 days after chest tube removal ( Figure 2A ) and followed up for 9 months with a normal diet ( Figure 2B ). Table 1 Common complications of these agents include chest pain, tachycardia, high fever, and dyspnea. Although talc is the most effective and favored sclerosing agent, it has serious complications including acute respiratory distress syndrome, acute pneumonitis, and pulmonary edema [6] .
Therefore, a number of investigations are being conducted to search for new agents for pleurodesis.
ABNOBA viscum F is a V. album extract known as an European mistletoe that grows on the genus Fraxinus trees.
V. album extract is a commonly used complementary anti-cancer drug in European countries. It can enhance life quality by decreasing the side effects of radiotherapy and chemotherapy, and also stimulates the immune system and improves survival [7] . A lot of literatures have reported favorable results by using the extract for chemical pleurodesis in the patient with malignant pleural effusion.
We also found it successful for managing congenital chylothorax [8] .
We initially performed standard conservative managements with chyle drainage through repeated thoracenteses and total parenteral nutrition and attempted to apply interferon alpha-2b. Unfortunately, the pleural drainage persisted for 2 months, and the patient was intolerable to the side effects. Because this was the first trial of intrapleural instillation of V. album extract in an adolescent who was refractory to management for chylothorax, the optimal dosage of V. album extract had not been established. The amount of the drug was determined bases on the dosage for prolonged pneumothorax and malignant pleural effusion in adult patients [6] . Although the usual starting dose of AB-NOBA viscum F is 100 mg, which can be increased to 500 mg in adults, we used two ampules (200 mg of ABNOBA viscum F) per pleurodesis because of the patient's lower body weight and her youth out of concern about potential side effects.
In conclusion, although Gorham disease is a very rare disorder, a concomitant chylothorax is a lethal complication and hardly treatable. The V. album extract is introduced as a modern sclerosing agent for chemical pleurodesis.
We suggest that chemical pleurodesis using an extract of V. album for intractable chylothorax in patients with Gorham disease is a reasonable treatment option, and a standardization of its use should be established through various experiences and long-term follow-up. 
